



Welcome to the NCCN 2023 Oncology Fellows Program

NCCN would like to thank the outstanding faculty who are presenting and all of you for attending this educational program. We hope you find the information presented useful to your practice, and we encourage you to attend future NCCN educational initiatives.

Agenda	Page 2
Accreditation Information	Pages 3 – 5
<i>Supporting Organizations</i>	<i>Page 3</i>
<i>Claiming CE Credit</i>	<i>Page 5</i>
Disclosure Information	Pages 6 – 9
Faculty Biographies	Pages 10 – 20



AGENDA

12:00 PM – 12:30 PM	Lunch and Registration
12:30 PM – 12:35 PM	Opening Remarks Crystal S. Denlinger, MD, <i>National Comprehensive Cancer Network</i>
12:35 PM – 1:20 PM	How to Optimize Systemic Therapy Outside of the Cancer Center: Best Practices for Managing Anticancer Therapies B. Douglas Smith, MD <i>The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</i>
1:25 PM – 2:25 PM	The Art of Creating and Sustaining Interprofessional Teams to Provide Comprehensive Care Throughout the Patient Journey Moderator: Wui-Jin Koh, MD, <i>National Comprehensive Cancer Network</i> Panelists: Gwen Darien, <i>National Patient Advocate Foundation</i> Susan E. Franco, RN, BSN, OCN, <i>Fred & Pamela Buffett Cancer Center</i> Timothy Kubal, MD, MBA, <i>Moffitt Cancer Center</i>
2:30 PM – 3:15 PM	Management of Central Nervous System Metastases L. Burt Nabors, MD, <i>O'Neal Comprehensive Cancer Center at UAB</i>
3:15 PM – 3:35 PM	Break
3:35 PM – 4:35 PM	Team-Based Management of Immunotherapy-Related Toxicities Bianca D. Santomasso, MD, PhD, <i>Memorial Sloan Kettering Cancer Center</i> Bryan J. Schneider, MD, <i>University of Michigan Rogel Cancer Center</i> Yinghong (Mimi) Wang, MD, PhD, <i>The University of Texas MD Anderson Cancer Center</i>
4:40 PM – 6:10 PM	An Exploration of Oncology Professions Beyond Research and Clinical Practice Moderator: Crystal S. Denlinger, MD, <i>National Comprehensive Cancer Network</i> Panelists: Jonathan D. Cheng, MD Senior Vice President; Therapeutic Area Head of Oncology Drug Development <i>Bristol Myers Squibb</i> Attending Physician; Associate Professor, <i>Fox Chase Cancer Center</i> Robert Coleman, MD Chief Medical Officer, <i>Sarah Cannon Research Institute (SCRI)</i> <i>The US Oncology Network</i> Yehoda M. Martei, MD, MSCE Vice Chief of Diversity, Inclusion and Health Equity Assistant Professor of Medicine, Hematology - Oncology Division Global Health Scholar, <i>Penn Center for Global Health</i> <i>Perelman School of Medicine, University of Pennsylvania</i> <i>Abramson Cancer Center at the University of Pennsylvania</i> Barbara L. McAneny, MD Chief Executive Officer, <i>New Mexico Cancer Center/NMOHC</i> <i>New Mexico Oncology Hematology Consultants, Ltd.</i> Former President, <i>American Medical Association</i>
6:10 PM – 6:15 PM	Closing Remarks Crystal S. Denlinger, MD; Wui-Jin Koh, MD <i>National Comprehensive Cancer Network</i>
6:15 PM – 7:30 PM	Fellows Networking Reception





Accreditation Information

Program Overview

Designed specifically for oncology fellows, this ½-day, CE-certified program seeks to educate future oncology practitioners about the application of the NCCN Guidelines®, evidence-based treatment principles for the management of significant cancer types, the implementation of supportive care in oncology, and recommendations for professional career development.

Intended Audience

This program is designed to meet the educational needs of second- and third-year medical, surgical, and radiation oncology fellows.

Goal of Education

The goal of this program is to ensure that oncology fellows, as members of the interprofessional oncology care team, have the knowledge and skills necessary to apply the standards of care to their practice and health care setting for patients with cancer.

Global Learning Objectives

Following this program, participants should be able to:

- Evaluate advances in the management of patients with cancer and key updates in the NCCN Guidelines® and apply appropriate treatment and supportive care strategies to optimize patient education and care.
- Review issues related to the following topics:
 - How to Optimize Systemic Therapy Outside of the Cancer Center: Best Practices for Managing Anticancer Therapies;
 - The Art of Creating and Sustaining Interprofessional Teams to Provide Comprehensive Care Throughout the Patient Journey;
 - Management of Central Nervous System Metastases;
 - Team-Based Management of Immunotherapy-Related Toxicities; and
 - An Exploration of Oncology Professions Beyond Research and Clinical Practice.

CE Supporters

This activity is supported by educational grants from: AstraZeneca; Coherus BioSciences; Genentech, a member of the Roche Group; Gilead Sciences, Inc.; GSK; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC Novartis; and NOVOCURE. This activity is supported by an independent educational grant from Bristol Myers Squibb. This educational activity is supported by a medical education grant from Exelixis, Inc. This activity is supported by a grant from Pfizer Inc. *(Updated 3/21/23)*

Joint Accreditation

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians

NCCN designates this live activity for a maximum of 5 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.



Accreditation Information

Session Learning Objectives

Following this program, participants should be able to:

How to Optimize Systemic Therapy Outside of the Cancer Center: Best Practices for Managing Anticancer Therapies

- Describe the challenges associated with the use of oral anticancer therapies.
- Discuss the strategies that can be utilized to optimize the use oral anticancer therapies.
- Identify the resources and requirements needed for the implementation of a treatment plan to improve the use of oral anticancer therapy in outpatient settings.

The Art of Creating and Sustaining Interprofessional Teams to Provide Comprehensive Care Throughout the Patient Journey

- Describe the spectrum of physical, emotional and psychosocial effects of cancer and cancer treatment on patients and survivors.
- Explain how various members of the interprofessional team can help support patients, survivors, and caregivers by providing education, managing side effects, and addressing psychosocial problems to maximize quality of life.
- Discuss approaches to building and maintaining effective multidisciplinary, interprofessional teams to provide comprehensive care to patients with cancer and survivors.

Management of Central Nervous System Metastases

- Describe advances in diagnosis and treatment of brain metastases.
- Understand the evidence supporting stereotactic radiosurgery and whole brain radiation therapy for treatment of brain metastases, as well as potential effects on cognitive function and quality of life.
- Identify emerging systemic therapy options for patients with brain metastases, including targeted therapies.

Team-Based Management of Immunotherapy-Related Toxicities

- Describe the different classes of cancer immunotherapy (i.e., ICIs and CAR-T therapy), and how immunotherapy-related toxicities differ from those elicited by traditional chemotherapy.
- Identify which organ systems are most commonly affected by immunotherapy-related toxicities and when disease specialist consultation may be warranted.
- Discuss multidisciplinary strategies to facilitate early diagnosis and treatment of immunotherapy-related toxicities.

An Exploration of Oncology Professions Beyond Research and Clinical Practice

- Identify professional opportunities for employment that do not involve direct patient care.
- Describe qualifications for various roles outside of the traditional clinical setting.
- Identify ways in which trainees can supplement their professional development during fellowship for any potential future career path in oncology.



Accreditation Information

How to Claim Credit

NCCN Account Verification

Before claiming credit, please ensure that you have an NCCN account and will receive the correct type of credit.

1. Log in at www.NCCN.org/login.
 - If you do not have an NCCN account, click “**Create Account**” to register one for free.
2. Click “Profile” in the left side menu.
3. Verify that your **User Type** matches the type of credit you will claim (see list below).
4. Scroll down and click “**Save**” if you make any changes.

User Types

- Physician/Surgeon/Oncologist = AMA PRA Category 1 Credits™; MOC points, if applicable*
- All other user types = certificate of participation

Claiming Credit

To claim your credits, log in with the same email address you used to register for the program:

1. Log in at <http://education.nccn.org/fellows2023>
2. Click the ‘**Take Course**’ button.
3. Follow the prompts to complete the evaluation and claim your credits.

Upon successful completion, you will be able to view/print/download your certificate.

If you have any questions or need further assistance, please contact the NCCN Continuing Education Department at education@nccn.org.



Disclosure Information

NCCN Continuing Education Disclosure Policy

It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose **ALL** financial relationships they have had in the past **24 months** with ineligible companies. The ACCME *Standards for Integrity and Independence* require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates, and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.

Definitions

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past **24 months** are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of **ALL** financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.



Disclosure Information

Faculty and Moderator Disclosures

The faculty listed below have **no relevant** financial relationship(s) with ineligible companies to disclose.

Gwen Darien
Susan E. Franco, RN, BSN, OCN
Wui-Jin Koh, MD
Yehoda M. Martei, MD, MSCE
Barbara L. McAneny, MD
Bryan J. Schneider, MD

The faculty listed below have the following **relevant** financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Jonathan D. Cheng, MD
Bristol-Myers Squibb Company: Equity Interest/Stock Options; Salary
Merck & Co., Inc.: Equity Interest/Stock Options

Robert L. Coleman, MD
AbbVie, Inc.: Grant/Research Support
AstraZeneca Pharmaceuticals LP: Grant/Research Support; Honoraria; Scientific Advisor
Caris Life Sciences: Scientific Advisor
Clovis Oncology: Grant/Research Support
Eisai Inc.: Scientific Advisor
Genentech, Inc.: Grant/Research Support
GlaxoSmithKline: Consulting Fee; Scientific Advisor
ImmunoGen, Inc.: Consulting Fee; Grant/Research Support; Honoraria; Scientific Advisor
Merck & Co., Inc.: Grant/Research Support; Scientific Advisor
Novocure: Grant/Research Support; Scientific Advisor
SeaGen: Grant/Research Support; Scientific Advisor

Crystal S. Denlinger, MD
Agiost, Inc.: Grant/Research Support
Amgen Inc.: Grant/Research Support
AstraZeneca Pharmaceuticals LP: Grant/Research Support
BeiGene: Scientific Advisor; Grant/Research Support
Bristol-Myers Squibb Company: Scientific Advisor; Grant/Research Support
Eli Lilly and Company: Grant/Research Support
Exelixis Inc.: Grant/Research Support
Genmab: Grant/Research Support
MacroGenics: Grant/Research Support
MedImmune Inc: Grant/Research Support
Merck & Co., Inc.: Scientific Advisor
sanofi-aventis U.S.: Grant/Research Support
Taiho Pharmaceuticals Co., Ltd.: Scientific Advisor
Zymeworks: Scientific Advisor; Grant/Research Support

Timothy Kubal, MD, MBA
Apellis Pharmaceuticals: Consulting Fee



Disclosure Information

Faculty and Moderator Disclosures (continued)

The faculty listed below have the following **relevant** financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

L. Burt Nabors, MD

Chimerix: Scientific Advisor

Bianca D. Santomasso, MD, PhD

Bristol-Myers Squibb Company: Consulting Fee

Gilead Sciences, Inc.: Consulting Fee

IN8BIO, Inc.: Scientific Advisor

Incyte Corporation: Consulting Fee

Janssen Pharmaceutica Products, LP: Consulting Fee

Legend Biotech: Consulting Fee

B. Douglas Smith, MD

Bristol-Myers Squibb Company: Consulting Fee

Celgene Corporation: Consulting Fee

Celularity Inc.: Consulting Fee

Jubilant Pharma Limited: Scientific Advisor

Novartis Pharmaceuticals Corporation: Consulting Fee

Pfizer Inc.: Consulting Fee

Servier Pharmaceuticals LLC: Consulting Fee

Yinghong (Mimi) Wang, MD, PhD

AzurRx BioPharma: Consulting Fee

Ilya Pharma AB: Consulting Fee

MabQuest SA: Scientific Advisor

Sanarentero, LLC: Consulting Fee

Sorriso Pharmaceuticals: Consulting Fee

Springer: Royalty Income



Disclosure Information

NCCN Staff Disclosures

The planners listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Crystal S. Denlinger, MD

Agios, Inc.: Grant/Research Support

Amgen Inc.: Grant/Research Support

AstraZeneca Pharmaceuticals LP: Grant/Research Support

BeiGene: Scientific Advisor; Grant/Research Support

Bristol-Myers Squibb Company: Scientific Advisor; Grant/Research Support

Eli Lilly and Company: Grant/Research Support

Exelixis Inc.: Grant/Research Support

Genmab: Grant/Research Support

MacroGenics: Grant/Research Support

MedImmune Inc: Grant/Research Support

Merck & Co., Inc.: Scientific Advisor

sanofi-aventis U.S.: Grant/Research Support

Taiho Pharmaceuticals Co., Ltd.: Scientific Advisor

Zymeworks: Scientific Advisor; Grant/Research Support

None of the other planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.



Program Moderators

Crystal S. Denlinger, MD, is Senior Vice President, Chief Scientific Officer at the National Comprehensive Cancer Network (NCCN). As a member of NCCN's Senior Leadership Team, Dr. Denlinger helps steer strategic direction for the organization. She also oversees the NCCN Oncology Research Program, provides input into NCCN's Clinical Information Operations through oversight of the Drugs & Biologics and Biomarkers Compendia, and supports the planning and execution of NCCN's continuing education activities.

Dr. Denlinger earned her medical degree from the New Jersey Medical School, University of Medicine and Dentistry of New Jersey. She completed an internal medicine categorical residency at Mount Sinai Medical Center and a hematology/oncology fellowship at Fox Chase Cancer Center and Temple University Hospital. Prior to joining NCCN, Dr. Denlinger held several leadership positions with Fox Chase Cancer Center—an NCCN Member Institution—including Chief, Gastrointestinal Medical Oncology, Deputy Director of the Early Drug Development Phase 1 Program, Director of the Survivorship Program, and Associate Professor in the Department of Hematology/Oncology. She continues to see patients at Fox Chase Cancer Center in a limited, volunteer capacity.

Dr. Denlinger has been involved with NCCN for many years. She contributed to the development of several NCCN Guidelines, including serving as Chair of the NCCN Survivorship Panel and as a member of the NCCN Esophageal/Gastric Cancers Panel. She also served on the editorial board for *JNCCN—Journal of the National Comprehensive Cancer Network* and on multiple committees for the NCCN Oncology Research Program. She is a past-recipient of the NCCN Foundation's Young Investigator Award, as well as the NCCN Rodger Winn Award for her leadership, drive, and commitment in service to developing clinical practice guidelines.

Wui-Jin Koh, MD, is the Senior Vice President/Chief Medical Officer at the National Comprehensive Cancer Network (NCCN). In this role, he helps oversee the flagship NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) program. He also is responsible for medical leadership and oversight for NCCN's continuing medical education program and *JNCCN—Journal of the National Comprehensive Cancer Network* and represents the organization at clinical and scientific meetings. Dr. Koh also is actively involved in NCCN Global initiatives.

Prior to his role at NCCN, he served as Professor of Radiation Oncology at University of Washington and Medical Director for Radiation Oncology at Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance.

Dr. Koh earned his medical degree at Loma Linda University School of Medicine. He conducted his post-graduate training at the University of Washington Medical Center, completing a residency and internship in radiation oncology and a clinical fellowship in tumor imaging. He is board-certified in radiation oncology.

Dr. Koh's research interests include combined chemo-radiation strategies, cancer management guidelines development, and the role of imaging in radiotherapy and cancer care. He specialized in the management of gynecologic and gastrointestinal tract tumors and the use of brachytherapy and intraoperative radiotherapy. He has received multiple Education and National *Top Doctors* awards.

Dr. Koh is well-published and involved in numerous professional societies, including the Society of Gynecologic Oncology, the American Society for Therapeutic Radiology and Oncology, the American Society of Clinical Oncology, the Gynecologic Oncology Group, the Western Association of Gynecologic Oncology, and the International Gynecologic Cancer Society. He also previously served as a member of the NCI Gynecologic Cancer Steering Committee.



***How to Optimize Systemic Therapy Outside of the Cancer Center:
Best Practices for Managing Anticancer Therapies***

B. Douglas Smith, MD, is Professor of Oncology at Johns Hopkins University School of Medicine and Co-Director of Clinical Research Operations for the Division of Hematologic Malignancies at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

Dr. Smith joined the faculty of the Division of Hematologic Malignancies at the completion of his oncology fellowship. Dr. Smith is recognized as a national leader in novel therapeutics in leukemia. His research focuses on taking new and promising laboratory insights and developing them into biology-based treatment approaches for patients with acute myeloid leukemia (AML), chronic myeloid leukemia (CML), and myelodysplastic syndromes (MDS). He is administratively responsible for overseeing the clinical research program for the Division of Hematologic Malignancies, and he manages the clinical trials portfolio for the Leukemia Program.

Dr. Smith has a passion for teaching and education of trainees, and he has served on the Fellowship Executive Committee since 2009, focusing on the program's educational platforms. In recognition of his outstanding clinical care and teaching, Dr. Smith was elected into the Miller-Coulson Academy of Clinical Excellence at Johns Hopkins in 2020.

Dr. Smith has served on the NCCN CML Guidelines Panel for the past 18 years.



The Art of Creating and Sustaining Interprofessional Teams to Provide Comprehensive Care Throughout the Patient Journey

Gwen Darien is Executive Vice President for Patient Advocacy, Engagement and Education at the National Patient Advocate Foundation (NPAF), a non-profit organization dedicated to amplifying the voices of patients and advocating for better access to affordable, equitable, quality care.

In her current role, Gwen leads activities and programs that link Patient Advocate Foundation's (PAF) patient service programs with NPAF's direct patient service programs and system change initiatives, with a goal to improve access to affordable, equitable quality health care.

Gwen is a longtime patient advocate who has played leadership roles in some of the country's preeminent nonprofit organizations. A three-time cancer survivor, Gwen came into cancer advocacy to change the experiences and outcomes for patients who came after her. With a goal to change the public dialogue about cancer and other life-threatening illnesses, she established the first stand-alone advocacy entity in a professional cancer research organization at the American Association for Cancer Research (AACR). Later, she served as the Executive Director of the Samuel Waxman Cancer Research Foundation; Director of The Pathways Project; and Executive Vice President of Programs and Services at the Cancer Support Community. In each role, Gwen championed placing patients at the center of health system change in research, public policy, and direct services.

Gwen also has served on a wide range of program committees and workshop faculties. She is past-Chair of PCORI's Patient Engagement Advisory Panel and founding Chair of the Community Engagement in Genomics Working Group of the National Human Genome Research. Gwen also serves on the Board of Trustees of the USP and is a member of the National Cancer Policy Forum. Gwen also served as Chair of the NCI Directors' Consumer Liaison Group and was a member of the advisory board of the Health Advocacy Program at Sarah Lawrence College.

As a thought leader in the cancer and biomedical research communities, Gwen has written extensively about her experiences as an advocate and cancer survivor. A recent piece, Transformation: My Experience as a Patient and an Advocate in Three Chapters, appeared in the National Academy of Medicine Perspectives. She also was founding Editor-in-Chief of two award-winning publications for people with cancer and those who care for them - CR and MAMM magazines. Her media leadership was recognized by the Avon Foundation, which honored her as one of "the most powerful women in breast cancer."



The Art of Creating and Sustaining Interprofessional Teams to Provide Comprehensive Care Throughout the Patient Journey (continued)

Susan E. Franco, RN, BSN, OCN, was the Nurse Manager of Cancer Care Coordination at the Nebraska Medical Center and Fred & Pamela Buffett Cancer Center and just recently transitioned to a Nurse Care Coordinator role.

Ms. Franco completed her undergraduate and nursing studies at the Creighton University School of Nursing in Omaha, Nebraska. She is an oncology-certified nurse.

In her current role, Ms. Franco is part of a multidisciplinary team and manages day-to-day operations related to case management within the medical center. She has served in various roles related to care coordination within oncology for 35 years. In leadership roles, she has led program development, new patient coordination, and care coordination initiatives.

During her tenure at Nebraska Med, Ms. Franco has held several positions in inpatient, outpatient, and ambulatory settings, caring for patients with various types of cancer. She has served on a number of internal committees and participated in several projects focused on performance improvement, care delivery models, and multidisciplinary care coordination. Additionally, much of her work has been dedicated to staff professional development and patient and family education. She has coordinated and led educational classes on a variety of topics, including care for post-transplant patients, electronic medical health records systems, and oncology fellowship training. In all these roles, Ms. Franco has worked with a goal to provide patient-centered care and make a difference in patients' lives.

Ms. Franco is a member of several professional organizations, including the Academy of Oncology Nurse Navigators and the Oncology Nursing Society (ONS). She has presented at prominent national meetings, including the ASCO Quality Symposium, the ONS Annual Congress, and the Academy of Ambulatory Nursing Annual Conference. She also is a past recipient of the *Carrol Wilson Award*, given to the nurse who represents the highest ideals of the nursing profession.

Timothy Kubal, MD, MBA, is the Chair of Satellite Oncology and an Associate Professor of Malignant Hematology at Moffitt Cancer Center.

Dr. Kubal earned his medical degree from the Florida State University College of Medicine and completed his residency in internal medicine at the University of North Carolina. He subsequently completed his hematology/oncology fellowship at Moffitt Cancer Center while concurrently completing a Master's of Business Administration at the University of South Florida.

Dr. Kubal's expertise is in myeloid malignancies, with a particular focus in acute leukemias. In addition to his clinical practice, Dr. Kubal's roles and responsibilities include working to instill a patient-focused continuous improvement mindset across the organization.

Dr. Kubal holds memberships with the American Society of Hematology and the American Society of Clinical Oncology. He has authored numerous peer-reviewed articles that have been published in prominent scientific publications, such as *American Journal of Hematology*, *Journal of Oncology Practice*, *The American Journal of Medicine*, and *Clinical Pharmacology & Therapeutics*.

Dr. Kubal is Co-Chair of the NCCN Best Practices Committee. He also serves as a member of the NCCN Committee Chair Advisory Group.



Management of Central Nervous System Metastases

Louis Burt Nabors, MD, is Vice-Chair for Research of Neurology and Neurosurgery, Professor, and Director of the Division of Neuro-Oncology at the University of Alabama at Birmingham O'Neal Comprehensive Cancer Center.

Dr. Nabors earned his medical degree from the University of Tennessee. He later completed an internship in medicine at the National Naval Medical Center in Bethesda, Maryland, as well as a residency in neurology and a fellowship in neuro-oncology at the University of Alabama at Birmingham. He served as a United States Navy Flight Surgeon on active duty from 1991 -1995 and reserves from 1995 -2002.

Dr. Nabors research examines primary brain tumors, specifically focusing on the role of post-transcriptional regulation of gene expression, the acquisition and post-processing of magnetic resonance imaging data, and early phase clinical evaluation of novel cancer therapies.

Dr. Nabors is a member of the American Academy of Neurology, the American Society of Clinical Oncology, the American Neurological Association, and the Society for Neuro-Oncology. He also has served as an ad-hoc reviewer for multiple scientific journals and has authored or co-authored numerous journal articles, abstracts, and book chapters. He also serves on the editorial board for Neuro Oncology.

Dr. Nabors is Chair of the NCCN Central Nervous Systems Cancers Panel and an editorial board member for *JNCCN -Journal of the National Comprehensive Cancer Network*.



Team-Based Management of Immunotherapy-Related Toxicities

Bianca D. Santomaso, MD, PhD, is an Assistant Attending Physician in the Department of Neurology at Memorial Sloan Kettering Cancer Center.

After completing her undergraduate studies at Yale University, Dr. Santomaso attended the Tri-Institutional MD-PhD Program, obtaining her medical degree at Weill Cornell Medical College and her doctorate of philosophy in immunology from The Rockefeller University. She completed a residency in neurology at New York Presbyterian/Weill Cornell Medical Center, where she served as Chief Resident in her final year. She then completed a fellowship in neuro-oncology at Memorial Sloan Kettering Cancer Center.

As a neuro-oncologist and neurologist, Dr. Santomaso cares for people with primary and metastatic brain tumors as well as neurologic complications of cancer. She has additional clinical and research interests in central nervous system lymphoma and the neurologic complications of cancer immunotherapies, including CAR T-cell therapy and immune checkpoint inhibitors.

Dr. Santomaso's research focuses on understanding the mechanism of acute and chronic neurologic toxicities of cancer immunotherapies in order to develop novel interventions to improve patient outcomes.

Dr. Santomaso is a member of the NCCN Management of Immunotherapy-Related Toxicity Panel.

Bryan J. Schneider, MD, is Clinical Professor of Internal Medicine in the Division of Hematology/Oncology at the University of Michigan. He is a member of the Upper Aerodigestive Clinic at the University of Michigan Rogel Cancer Center.

Dr. Schneider received his medical degree from the Indiana University School of Medicine and completed an internal medicine residency at Indiana University Medical Center. Following his residency, Dr. Schneider was appointed Chief Resident and completed a hematology and medical oncology fellowship at the University of Michigan. He currently is the section head of Thoracic Oncology at the Rogel Cancer Center.

Dr. Schneider specializes in thoracic oncology, with a specific interest in developing new strategies for the treatment of lung and esophageal cancer. He conducts clinical research in these areas and treats patients with lung malignancies. He also has published extensively in peer-reviewed journals and written several book chapters.

Dr. Schneider is a member of the American College of Physicians, the International Association for the Study of Lung Cancer, and the Southwest Oncology Group. He previously served on the Experimental Therapeutics Study Section of the National Institutes of Health and the Grant Review Committee for the Department of Defense Congressionally Directed Medical Research Program for Lung Cancer Research.

Dr. Schneider is Co-Chair of ASCO's guideline for the Management of Immune-Related Adverse Events in patients Treated with Immune Checkpoint Inhibitor Therapy. He also is Vice-Chair of the NCCN Management of Immunotherapy-Related Toxicity Panel and a member of the NCCN Guidelines Steering Committee.



Team-Based Management of Immunotherapy-Related Toxicities (continued)

Yinghong (Mimi) Wang, MD, PhD, is Director of Fecal Microbiota Transplantation and Director of Inflammatory Bowel Disorders in the Department of Gastroenterology at The University of Texas MD Anderson Cancer Center (MDACC).

Dr. Wang received her master's of science degree in cardiovascular and respiratory sciences at the University of Calgary. She earned her medical degree from China Medical University and doctorate of philosophy in cellular and molecular physiology at The Johns Hopkins University. She then completed an internal medicine residency at Albany Medical Center, followed by a fellowship in gastroenterology at the Cleveland Clinic.

Dr. Wang has profound clinical experience from world renowned medical programs. Her specialized areas include inflammatory bowel disease (IBD), fecal microbiota transplantation (FMT), and cancer immunotherapy-induced gastrointestinal (GI) toxicities. She has broad research collaboration network worldwide and holds more than 100 peer-reviewed publications and numerous international conference presentations in her academic career.

At MDACC, Dr. Wang is recognized for her expertise in managing cancer immunotherapy-induced GI toxicities and her initiative in setting up IBD Clinic and FMT Service. She also has taken a leading role on the management of immunotherapy-related toxicities as Chair of the MD Anderson Institutional Immunotherapy Toxicity Working Group and recently published a book entitled Managing Immunotherapy Related Organ Toxicities, A Practical Guide.

Dr. Wang is an active clinical researcher. She and her team have launched multiple clinical trials, one of which resulted in a breakthrough, successful treatment for immunotherapy-induced colitis refractory to standard immunosuppressant by FMT as a compassionate treatment. This pioneering work was published on *Nature Medicine* with great impact in this field.

Dr. Wang is a member of several professional organizations, including the American College of Gastroenterology, the Crohn's and Colitis Foundation, and the Texas Society of Gastroenterology and Endoscopy. She also has extensive experience contributing to national guidelines for the treatment of immunotherapy-induced colitis, serving on panels for multiple national and international oncology societies and gastroenterology societies, including the NCCN Management of Immunotherapy-Related Toxicity Panel.



An Exploration of Oncology Professions Beyond Research and Clinical Practice

Jonathan D. Cheng, MD, is Senior Vice President of Clinical Oncology Therapeutic Area Head at Bristol Myers Squibb (BMS) and an Attending Physician and Associate Professor at Fox Chase Cancer Center. He previously held several positions at Merck, including Vice President Clinical Research in Late-Stage Oncology, Associate Vice President of Aerodigestive and Hematologic Malignancies, Executive Director of the Product Development Team Lead of Head/Neck Cancers, and Clinical Director of multiple early and late-stage clinical trials.

Dr. Cheng received his medical degree at the University of Minnesota Medical School, where he also completed a residency in internal medicine. He later completed medical oncology and gastrointestinal oncology fellowships at Roswell Park Cancer Institutes and a laboratory research fellowship at Fox Chase Cancer Center.

Dr. Cheng's clinical practice focuses on the diagnosis, treatment, and prevention of gastrointestinal malignancies, including colorectal, esophageal, pancreatic, stomach, and liver, gall bladder, and bile duct cancer. He is well-versed in the multitude of complex medical, emotional, and social issues faced by patients with these cancers. He uses this experience to guide patients through the range of therapeutic options, including the latest research findings and newest clinical trials.

In his current role at BMS, Dr. Cheng is responsible for the clinical development of novel therapeutics of the BMS oncology pipeline and leads a dedicated group of more than 50 oncology physicians and more than 150 clinical scientists. His translational research focuses on the importance of stroma that tumors utilize to grow and metastasize. He has served as the Principal Investigator of numerous cooperative group tumor microenvironment trials investigating new agents in colorectal, pancreas, esophageal, and gastric cancers. He also has authored and led multiple registration-enabling clinical trials and led the health authority submission and approvals for more than a dozen oncology indication across multiple compounds, including pembrolizumab and lenvatinib. Additionally, he has led dozens of Health Authority interactions globally including pre-supplemental biologics.

Dr. Cheng is actively involved in a number of professional organizations, including the American Society of Clinical Oncology. He also has held a number of leadership positions for the Food & Drug Administration (FDA), including Industry Representative of the FDA's Oncology Drug Advisory Committee, Therapeutic Area Supervisor and Representative for the FDA's License Application meetings, and member of the FDA Oncology Drug Advisory Committee. He also has held positions with the Oral Explanation of European Medicines Agency (EMA), the EMA Scientific Advisory Group for Oncology, and the EMA Scientific Advice Committee.



An Exploration of Oncology Professions Beyond Research and Clinical Practice (continued)

Robert L Coleman, MD, is a gynecologic oncologist and Chief Scientific Officer at US Oncology Research.

Dr. Coleman received his medical degree from Creighton University in Omaha, Nebraska. He then completed a residency in obstetrics and gynecology at the Northwestern Medicine Prentice Women's Hospital in Chicago, Illinois and a fellowship in gynecologic oncology at The University of Texas MD Anderson Cancer Center (MDACC) in Houston, Texas.

In his current role, Dr. Coleman is the senior-most clinician scientist on the US Oncology Network Leadership Team and manages the clinical trials oncology portfolio for US Oncology Research. He has a broad set of responsibilities focused on expanding the organization's research efforts and strengthening the culture of research across the Network. He works collaboratively with the Network and McKesson Leadership Teams in addition to manufacturers, laboratory and device companies, and physicians within the Network. Through these collaborations, Dr. Coleman develops and maintains the infrastructure needed for Network physicians to access and participate in research, enabling them to incorporate more novel therapies into their patients' treatment plans. His role also includes evaluating emerging technologies, digital platforms, and artificial intelligence strategies in order to accelerate research within the Network.

Dr. Coleman is an internationally recognized leader in gynecologic cancer research. His research interests include drug discovery and novel therapeutics for ovarian, uterine, cervical cancer, clinical trial development, and statistical design. He has extensive expertise in creating and managing research programs in various care delivery settings, and he has been instrumental in developing many of the promising treatments now available for gynecological cancer management. He has served as Principal Investigator (PI) or co-PI for several CTEP-funded and industry-supported prospective clinical trials and has authored or co-authored over 700 scientific publications, including over 360 peer-reviewed original research articles. He also has contributed to many book chapters and has edited and written six books.

Among his career highlights, Dr. Coleman pioneered numerous innovative surgical techniques for ovarian cancer management, led multiple clinical trials resulting in breakthrough therapies for the treatment of ovarian cancer, and mentored new generations of oncologic researchers and established new training techniques. Prior to his current role, Dr. Coleman served as a Professor and the Ann Rife Cox Chair of the Department of Gynecologic Oncology and Reproductive Medicine MDACC, where he also served as Executive Director of Cancer Network Research. He also serves as Co-Director of the Gynecologic Oncology Group (GOG) Partners Foundation, Inc. He is the immediate Past-President of both the International Gynecologic Cancer Society and the former President of the Society of Oncologic Gynecology (SGO). He has received a number of awards throughout his career in recognition of his accomplishments in teaching and research, including the APGO/CREOG award in teaching and the 2023 SGO's Innovator in Cancer Research Award.



An Exploration of Oncology Professions Beyond Research and Clinical Practice (continued)

Yehoda M. Martei, MD, MSCE, is Vice Chief of Diversity, Inclusion, and Health Equity at the Perelman School of Medicine at the University of Pennsylvania, an Assistant Professor of Medicine in the Division of Hematology – Oncology, and a Global Health Scholar in the Penn Center for Global Health. She is also an Attending Physician at the University's Abramson Cancer Center.

Dr. Martei received her medical degree from Yale University School of Medicine. She completed her residency at the University of California, San Francisco (UCSF) Medical Center, and Hematology - Oncology fellowship at the Hospital of the University of Pennsylvania, where she also received a master's of science degree in clinical epidemiology. She is board-certified in internal medicine with a sub-specialty in medical oncology.

Dr. Martei specializes in breast cancer and global health. Her research goals are to improve access to cancer therapy in low-income countries and low-resource communities and improve outcomes in breast cancer patients, including people living with HIV in sub-Saharan Africa, using implementation science.

Dr. Martei's current projects include evaluation of access to WHO essential cancer medicines and their impact on suboptimal cancer therapy delivery. She is a recipient of a Fogarty International Center K01 career development award to study the adaptation and fidelity of breast cancer guidelines in Botswana.

Dr. Martei has worked with prominent oncology organizations to improve and advance cancer care globally. Among these efforts, she serves as a technical consultant for the WHO Breast Cancer Initiative and a technical consultant on the task team for the Access to Oncology Medicines Consortium led by the Union for International Cancer Control. She also worked with the WHO Steering Committee and the Union for International Cancer Control Task Team to update the 2017 Model List of Essential Medicines for Cancer.

An Exploration of Oncology Professions Beyond Research and Clinical Practice (continued)

Barbara L. McAneny, MD, is the Chief Executive Officer of the New Mexico Cancer Center/New Mexico Oncology Hematology Consultants, Ltd. (NMOHC) and a former President of the American Medical Association (AMA).

Dr. McAneny graduated *magna cum laude* from the University of Minnesota and with honors from the University of Iowa College of Medicine. She completed her residency in internal medicine at the University of Iowa and her fellowship in hematology/oncology at the University of New Mexico.

Dr. McAneny is a practicing medical oncologist/hematologist and co-founder of NMOHC with Clark Haskins, MD. As a managing partner of the practice, she built the New Mexico Cancer Center as the first physician-owned, multi-disciplinary cancer center in the state with clinics in two locations. She also founded the New Mexico Cancer Center Foundation, which provides grants to help patients with nonmedical expenses. Additionally, Dr. McAneny is one of the founders and current Chair of the Board of the National Cancer Care Alliance, a group of independent practices collaborating to use innovation to deliver high-quality, high-value cancer care and to develop new alternative payment models based on sound data-driven principles. Prior to this, she was a founding member of Oncology Circle, a group of oncology practices using data to promote best practices.

Dr. McAneny's interest in using data to improve practice sustainability began when she was appointed to the Centers for Medicare & Medicaid Service's Practicing Physicians Advisory Council. Later, she received a \$19.8 million grant from the Centers for Medicare & Medicaid Innovation to demonstrate how oncology practices could use triage pathways to dramatically lower costs while improving outcomes. This award, named *COME HOME* (for Community Oncology Medical Home), later was incorporated into Medicare's Oncology Care Model.

Dr. McAneny has long-standing history of leadership involvement in local and national professional organizations. She is a Fellow and former member of the Board of Directors of the American Society of Clinical Oncology (ASCO), a Master of the American College of Physicians, and Past-President of several organizations, including the New Mexico Medical Society (NMMS), the Greater Albuquerque Medical Association, and the New Mexico chapter of the American College of Physicians. Additionally, she serves as a member of the Community Oncology Alliance Board of Trustees and on the Board of Directors of the Cancer Center Business Summit.

Dr. McAneny's involvement the AMA evolved over a number of years. She became ASCO's delegate to the AMA in 2002 and was elected to the AMA Council on Medical Service a year later, serving as its Chair from 2009 to 2010. She has been a member of the AMA Board of Trustees since June 2010, serving as its Chair from 2015 to 2016, and became the 173rd President of the AMA in June 2018.

Among other volunteer activities, Dr. McAneny has served on the governor of New Mexico's Task Force on Prenatal Care, the Board of Planned Parenthood of New Mexico, and as Chair of the Joint Task Force of the NMMS and the New Mexico Bar Association on domestic violence. She also has received a number of awards throughout her career, including New Mexico's *Woman on the Move Award* and *Woman of Influence Award*, as well as *Albuquerque The Magazine's* "Top Doc" Award.